Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Karyopharm Therapeut (KPTI)

Karyopharm Therapeut (KPTI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 99,791
  • Shares Outstanding, K 18,344
  • Annual Sales, $ 146,070 K
  • Annual Income, $ -196,040 K
  • EBIT $ -91 M
  • EBITDA $ -80 M
  • 60-Month Beta 0.13
  • Price/Sales 0.84
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 109.86% (-24.82%)
  • Historical Volatility 117.29%
  • IV Percentile 10%
  • IV Rank 4.51%
  • IV High 558.15% on 03/19/26
  • IV Low 88.67% on 12/11/25
  • Expected Move (DTE 23) 1.25 (23.98%)
  • Put/Call Vol Ratio 2.03
  • Today's Volume 956
  • Volume Avg (30-Day) 8,609
  • Put/Call OI Ratio 0.49
  • Today's Open Interest 93,805
  • Open Int (30-Day) 81,713
  • Expected Range 3.96 to 6.46

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -1.35
  • Number of Estimates 3
  • High Estimate -0.76
  • Low Estimate -2.12
  • Prior Year -2.77
  • Growth Rate Est. (year over year) +51.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.09 +2.36%
on 03/25/26
10.11 -48.47%
on 02/26/26
-4.88 (-48.36%)
since 02/25/26
3-Month
5.09 +2.36%
on 03/25/26
10.99 -52.59%
on 02/24/26
-2.26 (-30.25%)
since 12/24/25
52-Week
3.51 +48.43%
on 04/01/25
10.99 -52.59%
on 02/24/26
-0.39 (-6.96%)
since 03/25/25

Most Recent Stories

More News
Karyopharm Announces $30 Million Private Placement with RA Capital

NEWTON, Mass. , March 24, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has...

KPTI : 5.21 (-4.23%)
Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction

– While Similar Symptom Improvement Was Observed Across the Two Arms Relative to Baseline, SENTRY Did Not Meet its Second Co-Primary Endpoint of Abs-TSS –

KPTI : 5.21 (-4.23%)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWTON, Mass. , March 2, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company...

KPTI : 5.21 (-4.23%)
Karyopharm Therapeutics: Q4 Earnings Snapshot

Karyopharm Therapeutics: Q4 Earnings Snapshot

KPTI : 5.21 (-4.23%)
Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress

–  Top-Line Data from the Phase 3 SENTRY Trial in Myelofibrosis on Track for March 2026 –

KPTI : 5.21 (-4.23%)
Karyopharm to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026

-- Conference Call Scheduled for Thursday, February 12, 2026, at 8:00 a.m. ET --

KPTI : 5.21 (-4.23%)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWTON, Mass. , Feb. 2, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company...

KPTI : 5.21 (-4.23%)
Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026

– Top-Line Data from the Phase 3 SENTRY Trial in Myelofibrosis on Track for March 2026 –

KPTI : 5.21 (-4.23%)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWTON, Mass. , Jan. 2, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company...

KPTI : 5.21 (-4.23%)
Breakthrough ASH Data Drives Blood Cancer Market To $240B Valuation

Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – The 2025 American Society of Hematology meeting showcased pivotal advances in blood cancer treatment, with...

PTGX : 104.31 (+3.90%)
KPTI : 5.21 (-4.23%)
GTBP : 0.4650 (-2.13%)
GSK : 54.70 (+3.31%)
TAK : 18.29 (+1.39%)

Business Summary

Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States.

See More

Key Turning Points

3rd Resistance Point 6.20
2nd Resistance Point 5.96
1st Resistance Point 5.58
Last Price 5.21
1st Support Level 4.96
2nd Support Level 4.72
3rd Support Level 4.34

See More

52-Week High 10.99
Fibonacci 61.8% 8.13
Fibonacci 50% 7.25
Fibonacci 38.2% 6.37
Last Price 5.21
52-Week Low 3.51

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.